Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?
2010 (English)In: Experimental Neurology, ISSN 0014-4886, E-ISSN 1090-2430, Vol. 224, no 1, 37-47 p.Article, review/survey (Refereed) Published
There is now a large volume of data indicating that compounds activating cannabinoid CB(1) receptors, either directly or indirectly by preventing the breakdown of endogenous cannabinoids, can protect against neuronal damage produced by a variety of neuronal "insults". Given that such neurodegenerative stimuli result in increased endocannabinoid levels and that animals with genetic deletions of CB(1) receptors are more susceptible to the deleterious effects of such stimuli, a case can be made for an endogenous neuroprotective role of endocannabinoids. However, this is an oversimplification of the current literature, since (a) compounds released together with the endocannabinoids can contribute to the neuroprotective effect; (b) other proteins, such as TASK-1 and PPARalpha, are involved; (c) the CB(1) receptor antagonist/inverse agonist rimonabant has also been reported to have neuroprotective properties in a number of animal models of neurodegenerative disorders. Furthermore, the CB(2) receptor located on peripheral immune cells and activated microglia are potential targets for novel therapies. In terms of the clinical usefulness of targeting the endocannabinoid system for the treatment of neurodegenerative disorders, data are emerging, but important factors to be considered are windows of opportunity (for acute situations such as trauma and ischemia) and the functionality of the target receptors (for chronic neurodegenerative disorders such as Alzheimer's disease).
Place, publisher, year, edition, pages
Elsevier , 2010. Vol. 224, no 1, 37-47 p.
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:umu:diva-35627DOI: 10.1016/j.expneurol.2010.03.021ISI: 000279128400005PubMedID: 20353772OAI: oai:DiVA.org:umu-35627DiVA: diva2:345716